检索结果-南通市图书馆

CNVs Associated with Susceptibility to Cancers: A Mini-Review

Journal of Cancer Therapy 2015年第5期6卷 413-422页

作者： Tomoko Furuya yutaka suehiro Yukihisa Namiki Kohsuke Sasaki Department of Pathology Yamaguchi University Graduate School of Medicine Ube Japan Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of Medicine Ube Japan BraCare Genetics Inc. Shimonoseki Japan Research Institute for Animal Science in Biochemistry and Toxicology (RIAS) Sagamihara Japan JCHO Shimonoseki Medical Center Shimonoseki Japan

Copy number variations (CNVs) that are frequent in genome influence on susceptibility of various diseases including cancers. The present mini-review focuses on CNVs associated with susceptibility to the cancers. Since CNVs are different between cancer types, the analysis of the specific CNV makes it possible to estimate the susceptibility to the cancers of interest in individuals. Although it is true that available data on CNVs associated with cancer susceptibility are limited at present, accumulation of the data is accelerated with the research progression of CNVs in near future. Information on CNVs associated with cancer susceptibility is useful for not only cancer research but also personalized healthcare including cancer prevention.

关键词： CNV Cancer Susceptibility Carcinogenesis Cancer Genome Genomic Polymorphism

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function

引用

World Journal of Gastroenterology 2016年第32期22卷 7252-7263页

作者： Taro Takami Takahiro Yamasaki Issei Saeki Toshihiko Matsumoto yutaka suehiro Isao Sakaida Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of Medicine

Hepatocellular carcinoma(HCC) is one of the deadliest cancers in the world and is associated with a high risk of recurrence. The development of a wide range of new therapies is therefore essential. In this study, from the perspective of supportive therapy for the prevention of HCC recurrence and preservation of liver function in HCC patients, we surveyed a variety of different therapeutic agents. We show that branched chain amino acids(BCAA) supplementation and late evening snack with BCAA, strategies that address issues of protein-energy malnutrition, are important for liver cirrhotic patients with HCC. For chemoprevention of HCC recurrence, we show that viral control after radical treatment is important. We also reviewed the therapeutic potential of antiviral drugs, sorafenib, peretinoin, iron chelators. Sorafenib is a kinase inhibitor and a standard therapy in the treatment of advanced HCC. Peretinoin is a vitamin A-like molecule that targets the retinoid nuclear receptor to induce apoptosis and inhibit tumor growth in HCC cells. Iron chelators, such as deferoxamine and deferasirox, act to prevent cancer cell growth. These chelators may have potential as combination therapies in conjunction with peretinoin. Finally, we review the potential inhibitory effect of bone marrow cells on hepatocarcinogenesis.

关键词： Hepatocellular carcinoma Liver cirrhosis Branched-chain amino acids Late evening snack Iron chelators Bone marrow cells

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Treatment strategies for advanced hepatocellular carcinoma:Sorafenib vs hepatic arterial infusion chemotherapy

引用

World Journal of Hepatology 2018年第9期10卷 571-584页

作者： Issei Saeki Takahiro Yamasaki Masaki Maeda Takuro Hisanaga Takuya Iwamoto Koichi Fujisawa Toshihiko Matsumoto Isao Hidaka Yoshio Marumoto Tsuyoshi Ishikawa Naoki Yamamoto yutaka suehiro Taro Takami Isao Sakaida Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of MedicineYamaguchi 755-8505Japan Department of Oncology and Laboratory Medicine Yamaguchi University Graduate School of MedicineYamaguchi 755-8505Japan Department of Medical Education Yamaguchi University Graduate School of MedicineYamaguchi 755-8505Japan Center of Research and Education for Regenerative Medicine Yamaguchi University Graduate School of MedicineYamaguchi755-8505Japan Center for Clinical Research Yamaguchi University HospitalYamaguchi 755-8505Japan Yamaguchi University Health Administration Center Yamaguchi 753-8511Japan

Sorafenib is used worldwide as a first-line standardsystemic agent for advanced hepatocellular carcinoma(HCC) on the basis of the results of two large-scale Phase Ⅲ trials. Conversely,hepatic arterial infusion chemotherapy(HAIC) is one of the most recommended treatments in Japan. Although there have been no randomized controlled trials comparing sorafenib with HAIC,several retrospective analyses have shown no significant differences in survival between the two therapies. Outcomes are favorable for HCC patients exhibiting macroscopic vascular invasion when treated with HAIC rather than sorafenib,whereas in HCC patients exhibiting extrahepatic spread or resistance to transcatheter arterial chemoembolization,good outcomes are achieved by treatment with sorafenib rather than HAIC. Additionally,sorafenib is generally used to treat patients with Child-Pugh A,while HAIC is indicated for those with either Child-Pugh A or B. Based on these findings,we reviewed treatment strategies for advanced HCC. We propose that sorafenib might be used as a first-line treatment for advanced HCC patients without macroscopic vascular invasion or Child-Pugh A,while HAIC is recommended for those with macroscopic vascular invasion or Child-Pugh A or B. Additional research is required to determine the best second-line treatment for HAIC non-responders with Child-Pugh B through future clinical trials.

关键词： Treatment strategy Hepatic arterial infusion chemotherapy Sorafenib Hepatocellular carcinoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：